AU2008203320A1 - Method for reducing acne or improving skin tone - Google Patents
Method for reducing acne or improving skin tone Download PDFInfo
- Publication number
- AU2008203320A1 AU2008203320A1 AU2008203320A AU2008203320A AU2008203320A1 AU 2008203320 A1 AU2008203320 A1 AU 2008203320A1 AU 2008203320 A AU2008203320 A AU 2008203320A AU 2008203320 A AU2008203320 A AU 2008203320A AU 2008203320 A1 AU2008203320 A1 AU 2008203320A1
- Authority
- AU
- Australia
- Prior art keywords
- acne
- stimuli
- skin
- mammal
- sensory regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 98
- 206010000496 acne Diseases 0.000 title claims description 59
- 208000002874 Acne Vulgaris Diseases 0.000 title claims description 55
- 230000001953 sensory effect Effects 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 59
- 239000003205 fragrance Substances 0.000 claims description 51
- 241000124008 Mammalia Species 0.000 claims description 47
- 230000003255 anti-acne Effects 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 45
- 230000003902 lesion Effects 0.000 claims description 41
- 230000035882 stress Effects 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 37
- 230000002040 relaxant effect Effects 0.000 claims description 34
- 230000009467 reduction Effects 0.000 claims description 30
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 29
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 29
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 28
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 claims description 27
- 239000000058 anti acne agent Substances 0.000 claims description 26
- 229940124340 antiacne agent Drugs 0.000 claims description 26
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 20
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 20
- 230000002996 emotional effect Effects 0.000 claims description 19
- 208000017520 skin disease Diseases 0.000 claims description 16
- 230000000007 visual effect Effects 0.000 claims description 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 229960002255 azelaic acid Drugs 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 10
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 10
- 229960004889 salicylic acid Drugs 0.000 claims description 10
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 9
- 229960005280 isotretinoin Drugs 0.000 claims description 9
- 229960001727 tretinoin Drugs 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 208000003251 Pruritus Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 210000001732 sebaceous gland Anatomy 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 5
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims description 5
- 229960004308 acetylcysteine Drugs 0.000 claims description 5
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 5
- 229960002916 adapalene Drugs 0.000 claims description 5
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 5
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 230000037326 chronic stress Effects 0.000 claims description 5
- 229960002227 clindamycin Drugs 0.000 claims description 5
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229960004275 glycolic acid Drugs 0.000 claims description 5
- 230000001339 gustatory effect Effects 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 229950001046 piroctone Drugs 0.000 claims description 5
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims description 5
- 229940107700 pyruvic acid Drugs 0.000 claims description 5
- 229960001755 resorcinol Drugs 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229960000565 tazarotene Drugs 0.000 claims description 5
- 229960003500 triclosan Drugs 0.000 claims description 5
- 229940045136 urea Drugs 0.000 claims description 5
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 229960000448 lactic acid Drugs 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- 229930002330 retinoic acid Natural products 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 229960005349 sulfur Drugs 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 84
- 239000002884 skin cream Substances 0.000 description 21
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 18
- 230000006872 improvement Effects 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 229960000890 hydrocortisone Drugs 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 210000002374 sebum Anatomy 0.000 description 8
- 230000002618 waking effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 101800000414 Corticotropin Proteins 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- -1 sticks Substances 0.000 description 3
- 241000195940 Bryophyta Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241001635598 Enicostema Species 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000009001 hormonal pathway Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0016—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the smell sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0022—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the tactile sense, e.g. vibrations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0044—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the sight sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0077—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with application of chemical or pharmacological stimulus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/04—Skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Acoustics & Sound (AREA)
- Psychology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
00 -1- 0
SAUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION SFOR A STANDARD PATENT oo 8
ORIGINAL
Name of Applicant: Johnson Johnson Consumer Companies, Inc.
Actual Inventors: Benjamin Wiegand and Laura McCulloch and Rachel Grossman and Lynn Ann Halas Address for Service is: SHELSTON IP Margaret Street Telephone No: (02) 9777 1111 SYDNEY NSW 2000 Facsimile No. (02) 9241 4666 CCN: 3710000352 Attorney Code: SW Invention Title: METHOD FOR REDUCING ACNE OR IMPROVING SKIN TONE Details of Original Application No. 2002359599 dated 04 Dec 2002 The following statement is a full description of this invention, including the best method of performing it known to me/us:- File: 42787AUP01 501635769_1.DOC/5844 00
O
1 METHOD FOR REDUCING ACNE OR IMPROVING SKIN TONE SCLAIM OF PRIORITY This application claims priority of U.S. Patent Application Serial No. 10/017,180 filed December 7, 2001 which is a continuation-in-part of U.S. Patent Application Serial No. 10/012,627, filed December 7, 2001, the disclosures of which are hereby incorporated C by reference.
00 SBACKGROUND OF THE INVENTION C1 1. Field of the Invention The present invention relates to methods for reducing the number and severity of acne lesions on the skin of a mammal; ameliorating the inflammation of acne lesions on the skin of a mammal; improving the skin tone of a mammal, (4) treating skin disorders; treating stress related skin diseases; reducing stress and improving the emotional well being of an acne sufferer; reducing sebaceous gland output; and increasins compliance of the administration of anti-acne products. The method comprises the administration of a sensory regimen in an amount effective to downregulate the activity of the hypothalamus-pituitary-adrenal (HPA) axis in combination with the administration of an anti-acne composition.
2. Description of the Prior Art Advances in technology in the last century have brought benefits to society but have resulted in greater prevalence of stress in the daily lives of people at all levels of society. Our stress response mechanisms have not adapted at the same pace as advancing technology. The effect of stress on health and well being is well documented in "Why Zebra's Don't Get Ulcers An Updated Guide to Stress, Stress Related Diseases and Coping" by Robert M. Sapolsky, ISBN 0-7167-3210-6, Chapter 1, 5 th Edition 2000) and in "The Concepts of Stress and Stress System Disorders Overview of Physical and Behavioral Homeostasis", JAMA, March 4, 1992, Vol. 267, No. 9. For 00 example, it is known that chronic stress (an accumulation of acute stresses) can cause or aggravate many conditions including immunosuppression and vulnerability to infectious diseases, gastric conditions, sleep problems, depression, premature birth in C expectant mothers, low birth weight, degeneration of brain neurons leading to memory and learning problems, elevated blood pressure, heart complications and stroke due to C elevated blood lipid levels and other health complications.
SWhile stress has a major effect on systemic health conditions, it also has been 0 proposed to play a role in one's skin condition. Skin diseases such as psoriasis, atopic Sdermatitis, itch, blotchiness, poor wound repair have all been proposed to be linked to C stress in some way. Some relevant references include Buske-Kirschbaum et al., Psychosomatic Medicine (1997), 59: 419-426; Denda et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol. 278: R367-R372, (2000); Dhabhar et al., Proc. Natl. Acad.
Sci., 1999, 96:1059-1064; Kabat-Zinn et al., Psychosomatic Medicine (1998) 60: 625- 632; Tausk et al., Arch. Dermatol., 2001 137: 78-82; Kiecolt-Glaser et al., Journal Behavioral Medicine 1986 9:5-21, Garg et al., Arch. Dermatol. 2001 137: 53-59; Slominski et al., Physiological Reviews, 2000 80: 979-1020; Panconesiet et al., Psychodermatology, 1996: 399-421; Scholzen, et al., Exp. Dermatol. 1998 81-96, the disclosures of which are hereby incorporated by reference.
Another skin condition potentially linked to stress is acne vulgaris. Acne vulgaris is a skin condition that affects over 85% of all people. The following are four primary factors that lead to the formation of acne vulgaris; increased sebum output resulting in oily, greasy skin; increased bacterial activity normally due to an overabundance of Propionibacterium acnes; plugging (hypercornification) of the follicle or pilosebaceous duct; and production of inflammation by substances leaking into the dermis which cause inflammatory reactions. A more detailed description can be found in Cunliffe, William Acne, London: Martin Duitz Ltd., 1989, Chapter 1, which is incorporated by reference.
These primary factors can be affected by some degree by varying hormone levels in people. One of the major reasons why acne is prevalent among the teen-age 00 populations is the dramatic increase in androgen output amongst that population which leads to increase sebum production. In addition, as hormone levels change in females during different times of their menstrual cycle, there is also a potential correlation with onset of acne lesions tied into their menstrual cycle.
Stress, which is present among both genders and all age groups, but clearly N present among the teen-age and 20 -30 year old populations, also can exacerbate and T lead to acne problems via a number of different pathways. For example, chronic stress 0 can lead to a reduction in the overall immune system, which would affect the skin's 00 Sability to fight off the Propionibacterium acnes bacteria.
It is known that a functioning immune system contributes to overall good health," including healthy skin. Researchers at Shiseido and Harvard Medical School and Massachusetts General Hospital, see, for example, www.shiseido.co.ip have hypothesized that use of make-up promotes a positive state of mind which in turn promotes beautiful skin through stimulation of the nervous system and internal secretions. Conversely they hypothesize that skin condition can deteriorate because of stress.
While a recognized benefit of the use of cosmetic and beauty products is that they can contribute to a more positive mental outlook, in general, use of cosmetic and beauty products has not been demonstrated to have a significant effect on the activity of the HPA axis to a degree wherein the quality of life an individual is improved. Indeed products that are intended to resolve a skin condition typically contain benefit agents that improve the skin condition by treating the outer layers of the skin. In addition, most products are either fragrance-free or lightly fragranced, which again would limit the product's ability to deliver any type of emotional benefit through sensory stimuli.
It is a common perception that emotional stress negatively affects skin condition. See for example, Journal of Investigative Dermatology Vol. 114, No. 4, April 2000 Abstract No. 415, p. 820 which is hereby incorporated by reference. In this abstract the researchers investigated the exacerbation of acne by emotional stress through looking at the effect of secretion of a neuropeptide ("substance secreted 00 O from nerve ending in response to emotional stress. In immunohistochemical studies in which they incubated human facial skin with substance P, they found expression of Sleukocytes (ELAM-1) and expression of a neuropeptide-degrading enzyme (NEP) in sebaceous glands. These findings imply that substance P could result in neurogenic inflammation and an effect on the sebaceous glands, such that acne may be exacerbated.
Other hormones are secreted in response to stressors which can be used as an indicator of stress. For example, the region in the brain known as the hypothalamus 0 drives the activity of the mammalian stress response. Specifically, the hypothalamus 00 drives the production of "stress hormones" including catecholamines and glucocorticoids. The hypothalamus responds to a stressor by activating the sympathetic nerve endings in the adrenal medulla to produce adrenaline. The hypothalamus produces corticotrophin-releasing hormone which acts upon the pituitary to release adrenocorticotrophic hormone ("ACTH") which in turn acts upon the adrenal cortex to promote the production of cortisol. The CRH and sympathetic systems participate in a positive feedback loop so that activation of one system activates the other. Since increased cortisol secretion is an indication that the HPA axis has been activated, conversely, a decrease in cortisol secretion would indicate a downregulation of HPA axis activity.
As discussed above, it is desirable to have a sustained reduction of stress related hormones in order to reduce acne, improve skin tone, and have a better quality of life.
Although there are over the counter commercially available anti-acne agents for topical use, such as salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, urea, resorcinol, N-acetylcysteine, retinoic acid, benzoyl peroxide, octopirox, triclosan, azelaic acid, phenoxyethanol, phenoxypropanol, flavinoids, derivatives thereof, and combinations thereof, they tend to be slow acting and may have negative side effects.
In general, current products are effective in reducing the clinical observation of acne but since it does not completely eliminate it the consumer is not completely satisfied with the treatment of their condition. Topical medication may also result in other 00 undesirable effects such as irritation and dryness. Accordingly, there remains a need to improve the effectiveness of currently available commercial acne products.
In addition to the products that are available over the counter, there are also a number of different pharmaceutical treatments that have been developed for the treatment of acne. These include, but are not limited to both topical and oral agents, for C example isotretinoin and tretinoin, adapalene, tazarotene, azelaic acid, minocycline, doxycycline, antibacterials such as erythromyacin and clindamycin, vitamins such as c zinc, folic acid and nicotinamide, as well as combinations of these antibacterials with over the counter anti-acne agents. However, there is a continuing desire to increase the effectiveness of these pharmaceutical compounds and to improve the user's quality of life.
This invention will solve the problem of improving acne and acne related conditions through use of sensory stimuli in combination with the use of an anti-acne agent. The methods according to the present invention reduce emotional stress, downregulate the HPA axis and improve the quality of life of the acne patient.
SUMMARY OF THE INVENTION The present invention relates to a method for reducing the number and severity of acne lesions on the skin of a mammal. The method comprises the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an effective amount of an anti-acne agent.
In other embodiments, the invention relates to methods for ameliorating the inflammation of acne lesions on the skin of a mammal and methods for improving the skin tone of a mammal using the method described above.
In yet another embodiment, the invention relates to a method for the treatment of skin disorders comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination 00 O with the administration of an anti-acne composition. Preferably, the method can provide at least at least two of the following treatments: reducing the number and t severity of acne lesions on the skin of a mammal; ameliorating the inflammation of acne lesions on the skin of a mammal; and improving the skin tone of a mammal.
The invention also relates to a method for the treatment of stress-related skin diseases such as atopic dermatitis, sebhorreic dermatitis, psoriasis, itch, wound healing, fine lines, wrinkles, pigmentation, and combinations thereof. The method comprises 00 the step of administering a sensory regimen in an amount effective to downregulate the Sactivity of the HPA axis of said mammal in combination with the administration of an active agent. As used herein, the term "active agent" means therapeutic agents known in the art to be useful in the treatment and or amelioration of the symptoms of these skin conditions.
In yet another embodiment, the invention also relates to a method for reducing stress and improving the emotional well being of an acne sufferer. The method comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an effective amount of an antiacne agent.
The invention also relates to a method for reducing the visual appearance of shine. The method comprises the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal.
In yet another embodiment, the invention relates to a method for reducing sebaceous gland output comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an effective amount of an anti-acne agent.
In another embodiment, the invention relates to a method for increasing compliance of anti-acne products comprising the step of administering a sensory regimen in combination with the administration of an anti-acne composition.
00 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS As discussed above, the methods according to the present invention can be used to reduce the number and severity of acne lesions on the skin of a mammal; (2) ameliorate the inflammation of acne lesions on the skin of a mammal; improve the C skin tone of a mammal, treat skin disorders; treat stress related skin diseases; rn, reduce stress and improve the emotional well being of an acne sufferer; reduce Ssebaceous gland output; and increase compliance of the administration of anti-acne 00 Sproducts. The method comprises the step of administering a sensory regimen in an (7 amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an effective amount of an anti-acne agent.
As used herein, "mammals" include any of a class of warm-blooded higher vertebrates that nourish their young with milk secreted by mammary glands and have skin usually more or less covered with hair, and non-exclusively includes humans, dogs and cats.
The term "effective amount" refers to the duration of the sensory regimen sufficient to create the desired response, reduction or down-regulation of the activity of the HPA axis and reduction of total daily adrenocortical hormone. The effective amount will vary with the age, physical, and emotional condition of the mammal being treated, the nature of concurrent therapy, the specific regimen employed, and like factors.
The sensory regimen can be any regimen that is relaxing to the user. Generally, the sensory regimen is selected from the group consisting of auditory stimuli, visual stimuli, tactile stimuli, gustatory stimuli and olfactory stimuli, and combinations thereof.
Suitable auditory stimuli include, but are not limited to, music and sounds of nature that are soothing or relaxing to the consumer. The term music is used herein to include instrumental and lyrical compositions; tunes; melodies; harmonies; songs; beats 00 O and frequencies such as those from metronomes, tuning forks, bells, beat machines, chimes; poetry and rhymes. The music may be of any genre, including, but not limited to, classical, soft rock, easy listening, progressive, country, and show tunes. The sounds of nature include, but are not limited to, animal sounds, such as whales singing or birds chirping; insect sounds, such as crickets; and sounds of the environment, such as a N, running stream or a waterfall. Sounds that have consistently soft dynamics with Cc minimal melodic and harmonic variability, having little or no conventional beat pitch, (7 little or no vocal, slow tempo, little or no percussion or strong rhythym are particularly 00 Seffective in relaxing or soothing the user. Sounds that use a binaural beat created by N, using two pure frequencies, usually one in each ear, are useful in improving the mood of the user. Binaural beats in the frequency range of delta, theta and alpha brain wave frequencies are useful for relaxing the user and beats in the frequency range of beta wave activity are useful for promoting mental alertness in the user. The auditory stimuli may include, but are not limited to, a cassette tape, video tape, compact disc, interactive toys and games, websites, and a computer audio file.
The visual stimuli may include, but are not limited to, soft lights, candles, videos, movies, paintings, murals, books, landscapes, interactive toys and games, websites, and computer image files that are soothing or relaxing to the consumer. The soft lights may be of any color, such as blue, green, pink, purple, and the like. Cool colors, such as blue and green hues, are preferred to soothe the user and aid relaxation; and warmer colors, such as oranges and reds are preferred to uplift the user. Pastel shades, which are low saturation hues, are useful in soothing the user. The light may be provided in the kit as a bulb, which can be inserted into a lamp at home, or may be provided in the kit as a lamp. Lights that utilize fiber optics may also be useful in the kits of this invention. The fiber optic lights may, as is known in the art, change colors intermittently. Soft lighting of approximately 500 lux is useful in relaxing the user, particularly in the evening hours prior to bedtime. Bright light of around 2000 lux or greater is useful in improving the mood of the user when used in the wakeful period of 00 0 the day such as at awakening or any other time during the day prior to the few hours preceding bedtime.
Combinations of light and sound that have frequency patterns in the range of delta, theta and alpha brain wave frequencies are useful for relaxing the user and those that have patterns in the frequency range of beta wave activity are useful for promoting r',I mental alertness in the user.
The tactile stimuli useful in the present invention includes, but is not limited to, 00 computer software, interactive toys and games, bubble baths, lotions, and personal care 0 Scompositions. "Personal care compositions" refers to personal cosmetic, toiletry, and healthcare products such as wipes, washes, baths, shampoos, gels, soaps, sticks, balms, sachets, pillows, mousses, sprays, lotions, creams, cleansing compositions, powders, oils, bath oils and other bath compositions which may be added to a bath. Personal care compositions may also include, but are not limited to, aerosols, candles, and substances that may be used with vaporizers. The aforementioned wipes, washes, baths, shampoos, gels, soaps, sticks, balms, sachets, pillows, mousses, sprays, lotions, creams, cleansing compositions, oils, bath oils, aerosols, candles and substances which may be used with vaporizers are commercially known to those who have a knowledge of preparing personal care compositions. One example of a suitable personal care composition is Johnson's Bedtime Bath®.
The computer software may be of an interactive nature, such that the consumer relaxes while utilizing the software. Such software includes video games, crossword puzzles and the like.
Gustatory experiences also help reduce stress. Therefore, the method of the invention may include food and beverages, such as, but not limited to, fruits, candies, crackers, cheese, teas, and the like.
The method of the invention may also include olfactory sensory experiences, such as fragrances. Fragrances that the user finds pleasant and to have a calming effect on their mood are useful in the practice of this invention. Suitable fragrances include 00
O
O relaxing fragrances, but are not limited to those perfume compositions described in UK application 0031047.4, now International Publication No. W002/49600 Al, the disclosure of which is hereby incorporated by reference. Also suitable are the 1 fragrances described in co-pending U.S. Patent Application Serial No. 09/676,876, filed September 29, 2000 entitled "Method For Calming Human Beings Using Personal CN Care Compositions", the disclosure of which is hereby incorporated by reference.
r Generally, the fragrance can be any fragrance that is perceivable and relaxing to the N, user and will downregulate the activity of the HPA axis. When the fragrance is present 00 O in the anti-acne composition, the stability of the fragrance in the presence of the anti- C acne agent should be such that it remains perceivable and relaxing to the user.
It is desirable to combine multiple sensory experiences useful for downregulating HPA activity and consequently reduce adrenocortical hormone below a baseline level. For example, a daily regime may include a fragrance; soft light; bubble bath containing fragrance; and relaxing music. The fragrance may be sniffed intermittently during the day while sitting in a softly lit room and listening to the relaxing music. The bubble bath containing fragrance may be used in the morning or at night when bathing or showering while listening to the relaxing music.
In a particularly prefered embodiment, the sensory regimen is administered daily for at least one week and comprises smelling a relaxing fragrance while soaking in a bath and listening to relaxing music. Further benefits are noticed when the sensory regimen includes soft lighting as described above.
The anti-acne compositions useful in the methods according to the invention include compositions containing anti-acne agents known in the art. Suitable anti-acne agents include, but are not limited to, salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, urea, resorcinol, N-acetylcysteine, retinoic acid, benzoyl peroxide, octopirox, triclosan, azelaic acid, phenoxyethanol, phenoxypropanol, flavinoids, derivatives thereof, and combinations thereof. Benzoyl peroxide and salicylic acid are preferred anti-acne agents. These anti-acne agents are used in amounts well known in the art for treatment of acne. For example, salicylic acid is generally used in amounts 00 ranging from about 0.5 to about 2% by weight of the composition. When benzoyl peroxide is used it is generally present at from about 2.5% to about 10% by weight of the composition.
In addition to the products that are available over the counter, there are also a number of different pharmaceutical treatments that have been developed for the ,I treatment of acne which are useful in the methods according to the invention. These include, but are not limited to both topical and oral agentsisotretinoin, adapalene 00 tretinoin, tazarotene and azelaic acid. The pharmaceutical anti-acne compounds are 00 used in a dosing amount that is in accordance with the prescribed directions of the N physician. While oral isotretinoin is effective for treating acne conditions, it is also know to have negative effects, such as depression, accordingly administration of isotretinoin in combination with the sensory regimen according to invention would be particularly beneficial.
In another embodiment of the invention, antibacterial agents known to be useful for treating acne and other skin disorders can be incorporated into the anti-acne compositions in combination with the anti-acne agents described above. Examples of suitable antibacterial agents include, but are not limited to, erythromycin and clindamycin. Generally, the antibacterial agent is used in amount that is in accordance with the prescribed directions of the dermatologist.
In the method of the invention, the anti-acne compositions are utilized as directed on the products, usually by topical application to the affected area several times daily. The effectiveness of the anti-acne composition is significantly improved through combining the use of sensory regimen with the topical application of the anti-acne agents.
As discussed above, it has been discovered that the administration of the above described sensory regimen in combination with the administration of the above described anti-acne composition can be used can be used to reduce the number and severity of acne lesions on the skin of a mammal; ameliorate the inflammation of acne lesions on the skin of a mammal; and improve the skin tone of a mammal.
00 0 Further, the reduction of acne, the amelioration of inflmmation of acne lesions and/or improved skin tone resulting from the inventive methods leads to an improved quality of life. Accordingly, in another embodiment the methods of the invention can be used for reducing stress and improving the emotional well being of an acne sufferer, the method comprising the step of administering a sensory regimen in an amount effective i to downregulate the activity of the HPA axis of said mammal in combination with the Cc administration of an anti-acne composition. In one embodiment, the stress is chronic N, stress.
00 SIn another embodiment, the methods according to the invention can be used for the treatment of skin disorders. As described above, the method comprises the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition, wherein said treatment comprises at least two of the following: (a) reducing the number and severity of acne lesions on the skin of a mammal; (b) ameliorating the inflammation of acne lesions on the skin of a mammal; and (c) improving the skin tone of a mammal.
The methods according to the invention can also be used for the treatment of stress-related skin diseases selected from the group consisting of atopic dermatitis, sebhorreic dermatitis, psoriasis, itch, wound healing, fine lines, wrinkles, pigmentation, and combinations thereof, comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an active agent. In one embodiment, the stressrelated skin disease is caused by chronic stress.
In another embodiment, the invention relates to a method for reducing the visual appearance of shine on human skin comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of the human. Such a method may further comprise the administration of an anti-acne composition.
00 O It has also been discovered that the administration of the above described sensory regimen in combination with the administration of the above described antiacne composition can be used can be used to reduce sebaceous gland output. Finally, because the administration of the sensory regimen is asethically pleasing to the user, the methods according to the invention can be used to increase compliance of the CN administration of anti-acne products.
Cc Examples are set forth below to further illustrate the nature of the invention and C the manner of carrying it out. However, the invention should not be considered as Sbeing limited to the details thereof.
EXAMPLES
Example 1 Effect of Relaxing Fragrance on Skin Condition Two groups of panelists (11 people per group) having mild to moderate acne 7 inflamed lesions, 5 non-inflamed lesions, and 2 nodules on the face) participated in a study to determine the effect of the addition of a relaxing fragrance in a benzoyl peroxide skin cream which they applied to their face daily. The basic formulation for the benzoyl peroxide skin cream used by Group I is listed below: Benzoyl Peroxide Skin Cream #1 Ingredient Percentage Laureth -4 0.4% Hydroxypropyl Methylcellulose 0.2% Carbomer 934P 1.75% Disodium EDTA 0.2% Sodium Hydroxide 0.29% Benzoyl peroxide 6.67% Water q.s.
The formulation for Benzoyl Peroxide Skin Cream #2 used by Group I was made by subtracting 0.2% water from the benzoyl peroxide skin cream #1 and replacing it with 0.2% fragrance (Quest PD-1861).
00 0 On day one, the participants' faces were evaluated for severity of acne in terms of the number of lesions and the type of lesions present.
'n Over the next two weeks, once a day, after washing with PURPOSETM C GENTLE CLEANSING WASH, commercially available from Johnson Johnson Consumer Companies, Inc., the panelists in each group squeezed approximately a pea sized amount of the benzoyl peroxide skin cream into the palm of the hand and applied it to the entire facial area except eye, lip, and mouth areas. The panelists were not 00 permitted to wash their faces for at least three hours after applying the cream.
00 SAt the end of the 2 week study, the panelists were asked what their overall C preference of the benzoyl peroxide skin cream they were using was and whether they agreed to the following statements: What was your overall preference? 1. The product treated whiteheads.
2. The product treated blackheads.
3. The product reduced the size of pimples.
4. The product made my skin feel smooth.
The product made my skin feel soft.
6. The product made my skin have even color.
7. The product made my skin have even texture.
8. The product was gentle to my skin.
9. The product was non-irritating to my skin.
The product was quickly absorbed by my skin.
11. The product did not make my skin flaky or have an ashy appearance.
12. The product reduced my skin pore size.
13. The product reduced my skin redness.
14. The product was good for dry skin.
The scale for overall preference was 0 (poor) to 10 (like extremely).
The scale for the statements was 1 (disagree) to 5 (strongly agree).
The results are shown in Table 1.
Table 1 Average Score Question Group 2 Group 1 Overall Preference** 7.3 5.9 Treat Whiteheads*** 3.9 3.4 Treat Blackheads*** 3.7 3.3 Reduced Size*** 4.1 Smooth Skin* 4.5 Soft Skin* 4.1 3.2 Even Skin Color* 3.5 2.7 Even Skin Texture* 3.8 3.1 Gentle* 4.5 Non-irritating* 4.3 3.4 Quick Absorption* 4.5 No Flaky, Ashy Appearance* 4.1 2.8 Reduced Pore Size* 3.7 2.9 Reduced Redness*** 3.8 3.3 Good For Dry Skin*** 3.5 95% significance 85% significance 80% significance Based on the data above, it is clear that the addition of fragrance to the benzoyl peroxide skin cream composition was perceived by the participants to significantly improve the performance of the product. Improvements were seen for every symptom that was inquired about.
00 0 O Example 2 Effect of Various Sensory Regimens on Skin Condition.
Z
Since there was a benefit observed with the addition of a relaxing fragrance in N the benzoyl peroxide skin cream containing an anti-acne agent, additional work was done to determine if additional relaxation treatments would further improve the skin N, condition and quality of life of the panelists. Groups 1 and 2 were idehtical to those in ¢€3 Example I and a third group with 12 panelists was studied where there were multiple 00 additional relaxation elements to the regime. 00 SThe following protocol was used for Group 3: Group 3 applied the topical Benzoyl Peroxide Skin Cream #1 once per day, smelled a fragrance PD1861 supplied by Quest Intemrnational while sitting and listening to relaxing music from the music CD entitled "Relax with Ocean Relaxing Surf' by Eclipse Music Group for 10 minutes three times a day, and at night took a 35C 15 minute bubble bath containing fragrance PD 1861 supplied by Quest International.
During the 10 minute fragrance music treatment, participants were instructed to take off the cap of a sorbarod and sniff the fragrance as often as they wished.
Initially, they were to think about the fragrance and the emotions that it brought and the scents that compose the fragrance. They were instructed to re-sniff the fragrance whenever they forgot or needed to refresh the fragrance image in their mind. While they were sniffing the fragrance, they were listening to the music using a personal CD player. Panelists were either sitting or lying down in a dimly lit room. During the bath exposure, panelists were provided with a fragranced bath product to use during the session. They were required to listen to a CD using a personal CD player during the bath. They also were required to dim the lights during their experience. The sensory procedure schedule was as follows: session 1 was 10 minutes of music and fragrance minutes after waking; session 2 was 10 minutes of music and fragrance 4 hours after waking; session 3 was 10 minutes of music and fragrance 8 hours after waking; session 4 was 15 minutes of fragranced bath and music 12 hours after waking (or just prior to bedtime).
After one week and at the end of the two-week period, the participants were again evaluated for severity ofacne. The results are shown in Tables 2 and 3.
Table 2 Reduction in Inflammatory Lesions Reduction In Inflammatory Lesions Group Number One Week Two Weeks 1 19 2 15 23 3 17 28 Table 3 Reduction in Total Lesions Reduction In Total Lesions Group Number One Week Two Weeks 1 12 2 NS 3 NS 12 NS no significant change The data demonstrates that the number of inflammatory lesions is reduced through the use of a skin cream with an anti-acne agent in it. Interestingly, it also appears that the addition of a relaxing fragrance, PD 1861 to the skin cream further reduced the number of lesions. The group that combined sensory experiences with the benzoyl peroxide skin cream demonstrated significant reduction in the number of inflammatory lesions after both the one and two week time points. Although, there appears to be less of a reduction in the total number of lesions after two weeks, it is important to note that inflammatory lesions are the most consumer noticeable symptom 00 0 O and product efficacy is often measured by the reduction in the number of inflammatory lesions.
It is interesting to note that there was a greater reduction of lesions on the second week of this study with the panelists who had some level of sensory treatment, either the use of a fragrance in the benzoyl peroxide skin cream, or the addition of N, relaxation elements to their regime. This is consistent with our hypothesis, as it would Sbe expected that there would be lag time between the "relaxation" effects that would be 00 present in the body, before they were manifested on the skin. The fact that there was a oO Sgreater improvement for the second week in both of the cases where sensory was applied vs. the baseline skin cream supports this theory.
Participants were also asked to fill out an Emotional questionnaire before and after the study to determine if they felt the treatments made them feel better. The questions were as follows: 1. Overall, how would you describe your CURRENT PHYSICAL STATE? Grading was from 0 to 10, with 0 being "not at all relaxed" and 10 being "extremely relaxed"; 2. Overall, how would you describe your CURRENT ENERGY LEVEL? Grading was from 0 to 10, with 0 being "no energy" and 10 being "extremely energized"; 3. Overall, how would you describe your CURRENT EMOTIONAL STATE? Grading was from 0 to 10, with 0 being "not at all relaxed" and 10 being "extremely relaxed"; 4. Overall, how would you describe your CURRENT STRESS LEVEL? Grading was from 0 to 10, with 0 being "no stress at all" and 10 being "extremely stressed".
The scores for each question before the study were compared to the scores for the same questions after the study. The data is reported in Table 4 as percent of score 00
O
improvement after treatment based on the average score for the entire group of participants. The statistical significance for the data is in parenthesis.
Table 4 Emotional Questionnaire C Percent Of Score Improvement n Question Group 1 Group 2 Group 3 0, 1 8(63) 5(72) 37(99)
O
2 13 (83) 5(75) 34 (96) 3 9(67) 3(63) 43 (99) 4 -13 (95) 3(65) 25 (97) Group 3 had a higher percent of participants feel better as a result of the treatment than any other group.
A second survey was performed before and after the study to establish if the participants felt the treatments were effective on their acne. The questionnaire that was used was the refined Skindex questionnaire that was published by Chren M, Lasek R, Flocke S Improved Discriminative and Evaluative Capability of a Refined Version of Skindex, a Quality-of-Life Instrument for Patients with Skin Diseases. Arch Dermatol.
1997; 133: 1433-1440 and is incorporated by reference. The statements were as follows: 1 My skin hurts; 2 My skin condition affects how well I sleep; 3 I worry that my skin condition may be serious; 4 My skin condition makes it hard to work or do hobbies; My skin condition affects my social life; 6 My skin condition makes me feel depressed; 7 My skin condition bums or stings; 8 I tend to stay at home because of my skin condition; 00 9 I worry about getting scars from my skin condition; My skin itches;
Z
11 My skin condition affects how close I can be with those I love; N 12 I am ashamed of my skin condition; 13 I worry that my skin condition may get worse; I 14 1 tend to do things by myself because of my skin condition; c 15 1 am angry about my skin condition; S16 Water bothers my skin condition (bathing, washing hands); 00 17 My skin condition makes showing affection difficult; S18 My skin is irritated; 19 My skin condition affects my interactions with others; I am embarrassed by my skin condition; 21 My skin condition is a problem for the people I love; 22 1 am frustrated by my skin condition; 23 My skin is sensitive; 24 My skin condition affects my desire to be with people; I am humiliated by my skin condition; 26 My skin condition bleeds; 27 I am annoyed by my skin condition; 28 My skin condition interferes with my sex life; 29 My skin condition makes me tired.
The statements were scored as follows: 1 never; 2 rarely; 3 sometimes; 4 often; 5 all the time. The scores for each question before the study were compared to the scores for the same questions after the study. The data is reported in Table 5 as percent of score improvement after treatment based on the average score for the entire group of participants. The score changes are represented by those indicating changes in symptoms, function, emotions, and on an overall basis.
Table 5 Quality of Life Questionnaire Percent Of Score Improvement Group Symptoms Functional Emotional Overall (questions 1, 7, (questions 2, 4, (questions 3, 6, 16, 18, 23, 5, 8, 11, 14, 17, 9, 12, 13, 15,20, 26) 19, 21, 24, 28, 22.25.27) 29) 1 2 8 -3 4 2 1 2 8 3 4 8 12 9 The Group 3 participants had improved scores on the questionnaire than the other treatments. Positive effects from the combination of an anti-acne agent with a sensory regimen were seen symptomatically, functionally, emotionally, and on an overall basis.
Example 3 Other Treatment Regimes Since there were clinical and perceived benefits of combining anti-acne skin creams with additional relaxation elements, additional studies were performed in an attempt to better delineate the relative contributions of both. In this separate study, Group 4 (13 panelists) applied benzoyl peroxide Skin Cream which was identical to benzoyl peroxide skin cream except the 6.67% of the 75% BPO was replaced with water. Group 5 (12 panelists), did not apply a benzoyl peroxide skin cream, but rather only participated in the identical Sensory regimen, as Group 3, which is listed below.
The following protocol was used for Group Group 5 smelled a fragrance PD1861 supplied by Quest International while sitting and listening to relaxing music from the music CD entitled "Relax with Ocean Relaxing Surf' by Eclipse Music Group for 00 O minutes three times a day, and took a 35 0 C 15 minute bubble bath at night containing fragrance PD 861 supplied by Quest International.
During the 10 minute fragrance music treatment, participants were instructed to take off the cap of a sorbarod and sniff the fragrance as often as they wished.
Initially, they were to think about the fragrance and the emotions that it brought and the scents that compose the fragrance. They were instructed to re-sniff the fragrance 3 whenever they forgot or needed to refresh the fragrance image in their mind. While 00 they were sniffing the fragrance, they were listening to the music using a personal CD 00 player. Panelists were either sitting or lying down in a dimly lit room. During the bath exposure, panelists were provided with a fragranced bath product to use during the session. They were required to listen to a CD using a personal CD player during the bath. They also were required to dim the lights during their experience. The sensory procedure schedule was as follows: session 1 was 10 minutes of music and fragrance 30 minutes after waking; session 2 was 10 minutes of music and fragrance 4 hours after waking; session 3 was 10 minutes of music and fragrance 8 hours after waking; session 4 was 15 minutes of fragranced bath and music 12 hours after waking (or prior to bedtime).
After one week and at the end of the two-week period, the participants were again evaluated for severity of acne using the modified Cook Global Acne Grading Scale described above. The results are shown in Tables 6 and 7.
Table 6 Reduction in Inflammatory Lesions Reduction In Inflammatory Lesions Group Number One Week Two Weeks 4 36 23 28 Table 7 Reduction in Total Lesions Reduction In Total Lesions Group Number One Week Two Weeks 4 29 33 14 7 The placebo Group 4 clearly improved significantly in terms of reduction of inflammatory lesions. This is thought to be at least partially due to improved hygiene during the study, the consumer expectation of the "treatment", and potentially to the benzoyl peroxide Skin Cream #3 itself. This is somewhat shown by the fact that the use of the relaxation elements by themselves show dramatic reductions in the number of inflammatory lesions. It is important to note that the study in Example 3 was performed at a different time of the year than Examples 1 and 2, so the results of Example 3 should not be compared to the results of Examples 1 and 2. As with the data relating to inflammatory lesions, the data for reduction in total number of lesions also showed that both treatments were effective, with the benzoyl peroxide skin cream being more effective.
Groups 4 and 5 also answered the Emotional and Skindex questionnaires described above about the ability of the treatments to make them feel better. Their results are listed in Tables 8 and 9 below.
Table 8 Emotional Questionnaire Percent Of Score Improvement Question Group 4 Group 1 13 (97) -8(58) 2 -1(66) 3(88) 3 8(70) 7 (84) 4 15(87) 11(90) Table 9 Quality of Life Questionnaire Percent Of Score Improvement Group Symptoms Functional Emotional Overall 4 1 4 10 6 0 10 6 7 These tables show that the relaxation treatment by itself showed broad emotional and well-being benefits to the panelists in this study. This is consistent with the clinical improvement that was seen in the panelist's acne condition. Improvements were also observed for Group 4, however, they did not seem to be as high as commensurate with the clinical improvement observed. Clearly, the optimal treatment for this condition combines both clinical and psychological benefits.
Since one of the factors that lead to acne is an increased amount of sebum, sebum production was measured for Groups 4 and 5 as well. It has been postulated that an increase in sebum could result after an increase in stress activity through an adrenocorticotrophic hormone pathway. An increase in sebum production could be related to an increase in the visual appearance of shine. The results are listed in Table Table 10- Effect of Treatments on Sebum reduction Study Cell Week 1 Reduction Week 2 Reduction Group 4 26% -2% Group 5 16% 8% Once again, the benefits for sebum reduction are observed in the cell with the relaxation elements in them. To further confirm this hypothesis, measures of stress markers were taken to determine changes in stress levels throughout the study.
00 Some participants were also asked to collect approximately I ml of saliva by
Z
Sdrooling or spitting into independent vials at set points throughout each day of the study for the purpose of measuring cortisol concentrations. Area under the curve measurements were taken as described in co-pending patent application "Methods For Measuring Stress In Mammals" 60/256,812 filed December 20th 2000 The area under the curve prior to the study was compared to the area under the curve after treatment.
00 The results are shown in Table 11 as percent decrease in area under the curve (reduction 00 in baseline cortisol levels).
Table 11 Percent Reduction In Cortisol Area Under The Curve Treatment One Week Two Weeks Group 4 19 Group 5 38 23 Group 5 had a decreased baseline cortisol level within one week, which lasted through the second week. This result correlated with the consumers' self-assessment, as well as the clinical data that was obtained. Separately, Group 4 (which had no inherent relaxation treatments beside the knowledge that the panelists were on a "treatment" study) showed a decrease in cortisol levels after one week. While a decrease was still seen after two weeks, the effect was not as sustained as was for Group 5 (having participated in the sensory regimen).
While we have shown that the reduction of cortisol has led to improved skin condition in the case of acne, this should also be effective for the treatment of other stress-related skin diseases, such as: atopic dermatitis, sebhorreic dermatitis, psoriasis, itch, wound healing, fine lines and wrinkles, pigmentation, etc.
Claims (36)
1. A method for reducing the number and severity of acne lesions on the skin of a mammal comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an 1 anti-acne agent.
2. A method according to claim 1, wherein the anti-acne composition is administered 0 orally or topically. S3. A method according to claim 2, wherein the anti-acne composition is administered topically and the anti-acne agent is selected from salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, urea, resorcinol, N-acetylcysteine, retinoic acid, benzoyl peroxide, octopirox, triclosan, azelaic acid, phenoxyethanol, phenoxypropanol, flavinoids, derivatives thereof, and mixtures thereof.
4. A method according to claim 3, wherein the anti-acne agent is selected from benzoyl peroxide, salicylic acid, and mixtures thereof. A method according to claim 2, wherein the anti-acne agent is a pharmaceutical compound selected from isotretinoin and tretinoin, adapalene, tazarotene, azelaic acid, minocycline, doxycycline, erythromycin and clindamycin and mixtures thereof.
6. A method according to claim 2, wherein the anti-acne composition is administered orally and is isotretinoin.
7. A method according to claim 2, wherein the anti-acne composition further comprises an antibacterial agent.
8. A method according to claim 1, wherein the sensory regimen is selected from the group consisting of auditory stimuli, visual stimuli, tactile stimuli, gustatory stimuli and olfactory stimuli, and combinations thereof.
9. A method according to claim 8, wherein the sensory regimen comprises olfactory stimuli provided by an effective amount of a relaxing fragrance present in the anti- acne composition. 00 O 10. A method according to claim 9, wherein the sensory regimen further includes visual stimuli comprising soft lighting. S11. A method according to claim 10, wherein the sensory regimen further includes auditory stimuli comprising music.
12. A method according to claim 1, wherein the sensory regimen is administered daily for at least one week and comprises olfactory stimuli comprising soaking in a bath Sfragranced with a relaxing fragrance in combination with auditory stimuli 00 comprising listening to relaxing music. S13. A method according to claim 12, wherein the sensory regimen further includes visual stimuli comprising soft lighting.
14. A method according to claim 1, wherein the reduced activity of the HPA axis results in a reduction in adrenocortical hormone levels of said mammal. A method of improving the quality of life of an individual by use of the method of claim 1.
16. A method for ameliorating the inflammation of acne lesions on the skin of a mammal comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition comprising an effective amount of an anti-acne agent.
17. A method according to claim 16, wherein the anti-acne composition is administered orally or topically.
18. A method according to claim 17, wherein the anti-acne composition is administered topically and the anti-acne agent is selected from salicylic acid, sulfur, lactic acid, glycolic acid, pyruvic acid, urea, resorcinol, N-acetylcysteine, retinoic acid, benzoyl peroxide, octopirox, triclosan, azelaic acid, phenoxyethanol, phenoxypropanol, flavinoids, derivatives thereof, and combinations thereof.
19. A method according to claim 18, wherein the anti-acne is selected from benzoyl peroxide, salicylic acid, or a combination thereof. 00 O 20. A method according to claim 16, wherein the anti-acne agent is a pharmaceutical compound selected from isotretinoin and tretinoin, adapalene, tazarotene, azelaic acid, minocycline, doxycycline, erythromycin and clindamycin and mixtures thereof.
21. A method according to claim 20, wherein the anti-acne composition is administered orally and is isotretinoin. Cc 22. A method according to claim 17, wherein the anti-acne composition further comprises San antibacterial agent. 00
23. A method according to claim 16, wherein the sensory regimen is selected from the C1 group consisting of auditory stimuli, visual stimuli, tactile stimuli, gustatory stimuli and olfactory stimuli, and combinations thereof.
24. A method according to claim 23, wherein the sensory regimen is administered daily for at least one week and comprises olfactory stimuli comprising smelling a relaxing fragrance in combination with auditory stimuli comprising listening to relaxing music. A method according to claim 24, wherein the sensory regimen further includes visual stimuli comprising soft lighting.
26. A method according to claim 16, wherein the sensory regimen is administered daily for at least one week and comprises olfactory stimuli comprising soaking in a bath fragranced with a relaxing fragrance in combination with auditory stimuli comprising listening to relaxing music for at least 10 minutes.
27. A method according to claim 26, wherein the sensory regimen further includes visual stimuli comprising soft lighting.
28. A method according to claim 16, wherein the reduced activity of the HPA axis results in a reduction in adrenocortical hormone levels of a mammal.
29. A method of improving the quality of life of an individual by use of the method of claim 16. A method of improving the skin tone of a mammal, comprising the step of administering a sensory regimen in an amount effective to downregulate the 00 O 0 activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition copmprising an effective amount of an anti-acne agent.
31. A method according to claim 30, wherein the anti-acne composition is cK, administered orally or topically.
32. A method according to claim 31, wherein the anti-acne composition is CN administered topically and the anti-acne agent is selected from salicylic acid, sulfur, Slactic acid, glycolic acid, pyruvic acid, urea, resorcinol, N-acetylcysteine, retinoic 00 acid, benzoyl peroxide, octopirox, triclosan, azelaic acid, phenoxyethanol, Sphenoxypropanol, flavinoids, derivatives thereof, and combinations thereof.
33. A method according to claim 32, wherein the anti-acne agent is selected from benzoyl peroxide, salicylic acid, or a combination thereof.
34. A method according to claim 31, wherein the anti-acne is a pharmaceutical compound selected from isotretinoin and tretinoin, adapalene, tazarotene, azelaic acid, minocycline, doxycycline, erythromycin and clindamycin and mixtures thereof. A method according to claim 34, wherein the anti-acne composition is administered orally and is isotretinoin.
36. A method according to claim 31, wherein the anti-acne composition further comprises an antibacterial agent.
37. A method according to claim 30, wherein the sensory regimen is selected from the group consisting of auditory stimuli, visual stimuli, tactile stimuli, gustatory stimuli and olfactory stimuli, and combinations thereof.
38. A method according to claim 37, wherein the sensory regimen is administered daily for at least one week and comprises olfactory stimuli comprising smelling a relaxing fragrance in combination with auditory stimuli comprising listening to relaxing music.
39. A method according to claim 38, wherein the sensory regimen further includes visual stimuli comprising soft lighting. 00 O 40. A method according to claim 30, wherein the sensory regimen is adfiinistered daily for at least one week and comprises olfactory stimuli comprising soaking in a bath Z n fragranced with a relaxing fragrance in combination with auditory stimuli comprising listening to relaxing music.
41. A method according to claim 40, wherein the sensory regimen further includes ri visual stimuli comprising soft lighting. Cc 42. A method according to claim 30, wherein the reduced activity of the HPA axis results in a reduction in adrenocortical hormone levels of a mammal. 00 S43. A method of improving the quality of life of an individual by use of the method of claim
44. A method for the treatment of skin disorders comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition, wherein said treatment comprises at least two of the following: (a) reducing the number and severity of acne lesions on the skin of a mammal; (b) ameliorating the inflammation of acne lesions on the skin of a mammal; and (c) improving the skin tone of a mammal. A method for the treatment of stress-related skin diseases selected from the group consisting of atopic dermatitis, sebhorreic dermatitis, psoriasis, itch, wound healing, fine lines, wrinkles, pigmentation, and combinations thereof, comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an active agent.
46. A method according to claim 45, wherein the stress-related skin disease is caused by chronic stress.
47. A method for reducing stress and improving the emotional well being of an acne sufferer, the method comprising the step of administering a sensory regimen in an amount effective to downregulate the activity of the HPA axis of said mammal in combination with the administration of an anti-acne composition. 00 O 3
48. A method according to claim 47, wherein the stress is chronic stress.
49. A method for reducing the visual appearance of shine on human skin comprising 'In the step of administering a sensory regimen in an amount effective to downregulate C the activity of the HPA axis of the human. A method according to claim 49, further including the administration of an anti- C acne composition.
51. A method for reducing sebaceous gland output comprising the step of administering 0 0 a sensory regimen in an amount effective to downregulate the activity of the HPA O axis of said mammal in combination with the administration of an anti-acne composition.
52. A method for increasing compliance of anti-acne products comprising the step of administering a sensory regimen in combination with the administration of an anti- acne composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008203320A AU2008203320A1 (en) | 2001-12-07 | 2008-07-25 | Method for reducing acne or improving skin tone |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/017,180 | 2001-12-07 | ||
| US10/017,180 US20020151527A1 (en) | 2000-12-20 | 2001-12-07 | Method for reducing acne or improving skin tone |
| US10/012,627 | 2001-12-07 | ||
| US10/012,627 US20020146469A1 (en) | 2000-12-20 | 2001-12-07 | Methods for reducing chronic stress in mammals |
| PCT/US2002/038747 WO2003049769A2 (en) | 2001-12-07 | 2002-12-04 | Method for reducing acne or improving skin tone |
| AU2002359599A AU2002359599A1 (en) | 2001-12-07 | 2002-12-04 | Method for reducing acne or improving skin tone |
| AU2008203320A AU2008203320A1 (en) | 2001-12-07 | 2008-07-25 | Method for reducing acne or improving skin tone |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002359599A Division AU2002359599A1 (en) | 2001-12-07 | 2002-12-04 | Method for reducing acne or improving skin tone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2008203320A1 true AU2008203320A1 (en) | 2008-08-21 |
Family
ID=26683806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002359599A Abandoned AU2002359599A1 (en) | 2001-12-07 | 2002-12-04 | Method for reducing acne or improving skin tone |
| AU2008203320A Abandoned AU2008203320A1 (en) | 2001-12-07 | 2008-07-25 | Method for reducing acne or improving skin tone |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002359599A Abandoned AU2002359599A1 (en) | 2001-12-07 | 2002-12-04 | Method for reducing acne or improving skin tone |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1474170A1 (en) |
| JP (1) | JP2005517649A (en) |
| KR (1) | KR20040063166A (en) |
| CN (1) | CN1615152A (en) |
| AU (2) | AU2002359599A1 (en) |
| BR (1) | BR0214993A (en) |
| CA (1) | CA2469000A1 (en) |
| MX (1) | MXPA04005499A (en) |
| WO (1) | WO2003049769A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003005971A2 (en) * | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
| MX2007012101A (en) | 2005-03-30 | 2007-12-04 | Revance Therapeutics Inc | Compositions and methods for treating acne. |
| JP5109383B2 (en) * | 2007-01-31 | 2012-12-26 | 大正製薬株式会社 | Adapalene-containing external preparation composition |
| KR100861978B1 (en) * | 2007-03-22 | 2008-10-07 | 한국콜마 주식회사 | Cosmetic composition for the treatment of acne using azelaic acid and preparation method thereof |
| JP5522819B2 (en) * | 2008-01-29 | 2014-06-18 | 株式会社マンダム | Antibacterial composition and external preparation for skin |
| EP2318011A4 (en) * | 2008-07-17 | 2011-09-14 | Georgia Levis | Methods and materials for the treatment of acne |
| WO2012153884A1 (en) * | 2011-05-12 | 2012-11-15 | (주)아모레퍼시픽 | Composition having improved stability for ameliorating acne |
| JP5840437B2 (en) * | 2011-09-30 | 2016-01-06 | 日本メナード化粧品株式会社 | Anti-inflammatory agent |
| CN106420787B (en) * | 2016-08-26 | 2020-05-26 | 陈启红 | Acne cream and preparation method thereof |
| AU2019312562B2 (en) * | 2018-07-30 | 2025-05-01 | Curology, Inc. | Compositions and methods of treating acne and photoaging |
-
2002
- 2002-12-04 MX MXPA04005499A patent/MXPA04005499A/en unknown
- 2002-12-04 WO PCT/US2002/038747 patent/WO2003049769A2/en not_active Ceased
- 2002-12-04 AU AU2002359599A patent/AU2002359599A1/en not_active Abandoned
- 2002-12-04 JP JP2003550818A patent/JP2005517649A/en active Pending
- 2002-12-04 CN CNA028272994A patent/CN1615152A/en active Pending
- 2002-12-04 KR KR10-2004-7008776A patent/KR20040063166A/en not_active Ceased
- 2002-12-04 EP EP02794147A patent/EP1474170A1/en not_active Withdrawn
- 2002-12-04 CA CA002469000A patent/CA2469000A1/en not_active Abandoned
- 2002-12-04 BR BR0214993-1A patent/BR0214993A/en not_active IP Right Cessation
-
2008
- 2008-07-25 AU AU2008203320A patent/AU2008203320A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1474170A1 (en) | 2004-11-10 |
| KR20040063166A (en) | 2004-07-12 |
| MXPA04005499A (en) | 2005-04-19 |
| AU2002359599A1 (en) | 2003-06-23 |
| BR0214993A (en) | 2004-12-07 |
| CN1615152A (en) | 2005-05-11 |
| CA2469000A1 (en) | 2003-06-19 |
| JP2005517649A (en) | 2005-06-16 |
| WO2003049769A2 (en) | 2003-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008203320A1 (en) | Method for reducing acne or improving skin tone | |
| US20050112214A1 (en) | Method for reducing acne for improving skin tone | |
| US20070275102A9 (en) | Method of affecting sleep and sleep-related behaviors | |
| US20070141179A1 (en) | Methods for alleviating symptoms associated with menopause using sensory regimen | |
| Bergler-Czop et al. | Dermatological problems of the puberty | |
| US20020146469A1 (en) | Methods for reducing chronic stress in mammals | |
| CA2525465A1 (en) | Topical composition for transdermal administration | |
| Goldberg et al. | Acne and rosacea: epidemiology, diagnosis and treatment | |
| Pandya et al. | Evaluation of role of priming agents in salicylic acid peel: A comparative study | |
| Bilovol et al. | Cosmetology: textbook for the 2nd-year dentistry students (English medium) | |
| CA3017488A1 (en) | Cosmetic electro-acupuncture without needles and corneotherapy beauty treatment | |
| CA2551690A1 (en) | Compositions for use with skin | |
| AU2007207879A1 (en) | Methods for reducing chronic stress in mammals | |
| Jacknin | Smart Medicine for Your Skin: A Comprehensive Guide to Understanding Conventional and Alternative Therapies to Heal Common Skin Problems | |
| Day | 100 Questions and answers about acne | |
| Lotti et al. | Treatment pearls from Europe | |
| Kumari | Evaluation of Efficacy and Safety of Intense Pulse Light in Treatment of Facial Acne Vulgaris | |
| TWI325324B (en) | ||
| GILBERT et al. | Topical Tretinoin: A Versatile Option for Adult Female Acne | |
| AU2003200289A1 (en) | Method of affecting sleep and sleep-related behaviours | |
| Fried | Healing Adult Acne | |
| Robinson et al. | NEW YORK ACADEMY OF MEDICINE, SECTION OF DERMATOLOGY AND SYPHILIS | |
| Rad | Effectiveness of trichloroacetic acid peel in the treatment of post acne hyperpigmentation on the face | |
| Sanghvi | Crow’s Feet: Causes, Treatment, and Home Remedies | |
| Feb-March | Male ANDROGENETIC ALOPECIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |